Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced  that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries.

This strategic move enhances Accord B.V.'s commitment to improving global access to plasma-derived medicines and strengthens its ability to meet the increasing demand for life-saving plasma therapies worldwide.

Prothya Biosolutions is one of Europe's leading plasma fractionators, operating major facilities in Amsterdam and Brussels, along with plasma collection centres across Hungary. The company employs approximately 1,200 skilled professionals.

Advancing Global Access to Plasma

The integration of Prothya into Accord B.V., marks a significant expansion of Accord's plasma capabilities. By combining Prothya's proven expertise in Europe with Intas's large-scale fractionation infrastructure in India, the organisation will accelerate the development and availability of essential plasma-derived medicinal products (PDMPs) for patients in multiple regions.

"Our goal is to ensure that patients who depend on plasma-derived therapies can access reliable and high-quality treatments," said Paul Tredwell, Global CEO of Accord Healthcare. "Together with Prothya, we are better positioned to address the growing global need for plasma-derived medicines, providing patients worldwide with critical, often under-prescribed therapies."